Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Chromium Picolinate “Insulin Resistance” Qualified Health Claim Clears FDA

This article was originally published in The Tan Sheet

Executive Summary

FDA approved Nutrition 21's chromium picolinate qualified health claim for reduced risk of insulin resistance that can lead to type 2 diabetes, the firm stated Aug. 29

You may also be interested in...



Nutrition 21 Chromax Claims Should Reflect “Real World” Performance – NAD

Nutrition 21 should modify performance claims for its newly launched Chromax chromium picolinate product to "more closely mirror the results and limitations in the applicable studies," according to the National Advertising Division

Nutrition 21 Chromax Claims Should Reflect “Real World” Performance – NAD

Nutrition 21 should modify performance claims for its newly launched Chromax chromium picolinate product to "more closely mirror the results and limitations in the applicable studies," according to the National Advertising Division

Nutrition 21 Chromax Claims Should Reflect “Real World” Performance – NAD

Nutrition 21 should modify performance claims for its newly launched Chromax chromium picolinate product to "more closely mirror the results and limitations in the applicable studies," according to the National Advertising Division

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS098600

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel